Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518161

— · E

5bbc731f-f84a-58f1-8e6e-5bba46f6f3bc

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
  • ANGIOGENESIS+0.450
  • HEDGEHOG_SIGNALING+0.390
  • TGF_BETA_SIGNALING+0.360
  • APICAL_SURFACE+0.330
  • HYPOXIA+0.300
  • G2M_CHECKPOINT+0.260
  • MYC_TARGETS_V1+0.260
  • E2F_TARGETS+0.250
  • KRAS_SIGNALING_DN+0.250

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.490
  • ADIPOGENESIS-0.450
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
  • FATTY_ACID_METABOLISM-0.390
  • PEROXISOME-0.340
  • BILE_ACID_METABOLISM-0.280
  • HEME_METABOLISM-0.280
  • ALLOGRAFT_REJECTION-0.270
  • PROTEIN_SECRETION-0.270
  • DNA_REPAIR-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1218cda38-ec89-4e23-849b-93f1b5bd0655
colon-landscapes@1
——0.784
2SRR5903555
lung-landscapes@6
—cohortSQ10.765
3TCGA-A7-A4SE-01A-11R-A266-07
breast-umap@18
—E0.758
4TCGA-85-8288-01A-11R-2296-07
lung-landscapes@6
—cohortSQ10.757
5s_150324_2a
medullo-epn-umap@date-based
EPNSupratentorial EPN0.749
6TCGA-77-8145-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.733
7TCGA-F7-8298-01A-11R-2403-07
head-neck@1
——0.727
8TCGA-CV-6950-01A-11R-1915-07
head-neck@1
——0.726
9SJEPD004_D.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.725
10SRR8518392
breast-umap@18
—D0.725

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.460Inavolisib— uncovered
ANGIOGENESIS0.450Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.390Inavolisib— uncovered
TGF_BETA_SIGNALING0.360Inavolisib— uncovered
APICAL_SURFACE0.330Temsirolimus— uncovered
HYPOXIA0.300Idelalisib— uncovered
G2M_CHECKPOINT0.260Inavolisib— uncovered
MYC_TARGETS_V10.260Inavolisib— uncovered
E2F_TARGETS0.250Inavolisib— uncovered
KRAS_SIGNALING_DN0.250Remibrutinib— uncovered
MITOTIC_SPINDLE0.250Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.250Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.250Inavolisib— uncovered
UV_RESPONSE_DN0.220Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.180Inavolisib— uncovered
MYC_TARGETS_V20.170Idelalisib— uncovered
GLYCOLYSIS0.160Inavolisib— uncovered
APICAL_JUNCTION0.130Inavolisib— uncovered
NOTCH_SIGNALING0.080Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.070Idelalisib— uncovered